APMA News - April 2012 - (Page 24)

Rx ONLY INDICATIONS AND USAGE: NAFTIN (naftifine hydrochloride) Cream, 2% is indicated for the treatment of: interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organism Trichophyton rubrum in adult patients ≥18 years of age. CONTRAINDICATIONS: None. WARNINGS AND PRECAUTIONS: If irritation or sensitivity develops with the use of NAFTIN (naftifine hydrochloride) Cream, 2% treatment should be discontinued. Patients should be directed to contact their physician if these conditions develop following use of NAFTIN (naftifine hydrochloride) Cream, 2%. Information for Patients: 1. NAFTIN (naftifine hydrochloride) Cream, 2% is for topical use only. NAFTIN (naftifine hydrochloride) Cream, 2% is not intended for intravaginal or ophthalmic use. 2. If irritation or sensitivity develops with the use of NAFTIN (naftifine hydrochloride) Cream, 2% treatment should be discontinued and appropriate therapy instituted. Patients should be directed to contact their physician if these conditions develop following use of NAFTIN (naftifine hydrochloride) Cream, 2%. Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies to evaluate the carcinogenic potential of NAFTIN (naftifine hydrochloride) Cream, 2% have not been performed. Pregnancy: Pregnancy Category B. There are no adequate and well-controlled studies of NAFTIN (naftifine hydrochloride) Cream, 2% in pregnant women. Because animal reproduction studies are not always predictive of human response, NAFTIN (naftifine hydrochloride) Cream, 2% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when NAFTIN (naftifine hydrochloride) Cream, 2% is administered to a nursing woman. Pediatric Use: Safety and effectiveness in pediatric patients have not been established. The number of pediatric patients ≥12 years of age studied were too small to adequately assess safety and efficacy. ADVERSE REACTIONS: In clinical trials with NAFTIN (naftifine hydrochloride) Cream, 2% the most common adverse reaction (≥1%) was pruritus. At-large Member Positions Open on CPME The CPME Nominating Committee is seeking applications for three at-large positions on the council. Closed ballot elections to fill the positions will be held by CPME at its October 2012 meeting. The positions are for three-year terms that are renewable up to three consecutive terms. Refer to www.cpme.org for specific information regarding the council’s activities. Each applicant is asked describe in writing how he or she satisfies at least two of the following five eligibility requirements: Has been active for a period of at least two years as a director of an approved podiatric residency program Has been active for a period of at least two years as an academic administrator or a full-time faculty member at an accredited college of podiatric medicine or an accredited medical institution Has demonstrated leadership within the profession or distinguished himself or herself as a practitioner Has served actively on one of the council’s committees for a minimum of one full term Has served on at least three CPME on-site evaluation teams to colleges of podiatric medicine, residency programs, or continuing education programs • • • • • The applicant also is expected to demonstrate qualifications and experience in one of the following areas of need: a podiatric physician holding an appointment as a full-time faculty member at an accredited college of podiatric medicine a podiatric physician who is a current or former board or committee member of a CPME-recognized specialty board; the candidate should have experience with the function of CPME, such as service to the council as an on-site evaluator or member of a standing or ad hoc committee of the council a private practice podiatric physician who is involved in residency education and/or continuing podiatric medical education and possesses experience with the function of the council, such as service as a CPME on-site evaluator or member of a standing or ad hoc committee of the council • • • NAFTIN (naftifine hydrochloride) Cream, 2% is manufactured for Merz Pharmaceuticals, LLC, Greensboro, NC 27410 NAFTIN is a registered trademark of Merz Pharmaceuticals, LLC NaftiN is a registered trademark of Merz Pharmaceuticals LLC. © 2012 Merz Pharmaceuticals LLC. all rights reserved 2/12 In addition to the minimum requirements outlined above, the candidate is encouraged to describe other podiatric and non-podiatric experiences he or she has had that strengthen the applicant’s submission. Individuals seeking election to the council must submit a curriculum vitae and an application letter that addresses both the requirements and at least one of the areas of need specified in this announcement. By mail: CPME Director, 9312 Old Georgetown Road, Bethesda, MD 20814. By fax: 301-571-4903. By e-mail: artinkle man@apma.org. Applications received after June 15, 2012, will not be considered. 24 APMA News April 2012 http://www.NAFTIN.com http://www.cpme.org

Table of Contents for the Digital Edition of APMA News - April 2012

APMA News - April 2012
In This Issue
Contents
Gen Z and myFEET
Dr. Caporusso’s Inaugural Speech to the House of Delegates
The Nuts and Bolts of Your House
Residency Genesis: A Priority for the Profession
Forum Builds Profession-wide Consensus on Student Recruitment
APMA By the Decade: 1942–1951
Profiles in Progress: Postgraduate Education
2011 Podiatric Practice Survey: Insurance Plan Participation
Infection Control Issues in the Podiatric Setting
Committee Member Acknowledgements
Federal Advocacy Forum
APMAPAC Chair Report
IT Consultant
Visit the Nation’s Capital for The National
Annual Scientific Meeting Preliminary Program
Annual Scientific Meeting Registration Form
Annual Scientific Meeting Sponsors
Website Wisdom
Technofile
Small Business 101
APMA All Stars
In Short
Worthy of Note
Affiliates Corner
List of Affiliated Organizations
Insurance Advisor
New Members
Death Notices
APMAPAC Update
Development Update
Awards Nominations
Classified Advertising
Dates to Remember
Advertising Index
10 Questions
Your APMA

APMA News - April 2012